Scantox

Name

Scantox

Legal name

Scantox Holding Aps

Website

https://scantox.com

Company type

Private

Founded year

1977

Operating status

Operating

Headcount range

101–250 employees

Ownership category

akta.pro rank

Product category

Preclinical Contract Research Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

Toxicology & Safety Assessment CROs (GLP) (HLAGAAAC)

akta.pro secondary industries

Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB), Nonclinical Study Management & Regulatory Writing (IND-enabling) (HLAGAFAN), Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA)

Keywords

• Preclinical contract research
• Genetic toxicology testing
• Regulatory toxicology services
• CNS drug discovery
• Pharmaceutical development services

Headquarters

HQ city

Lille Skensved

HQ country

Denmark

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Contract Research Services: Fee-for-service preclinical contract research including discovery services, genetic toxicology testing, regulatory toxicology studies, and pharmaceutical development/analytical services. Revenue is project-based, earned through contractual agreements with pharmaceutical, biotech, and medical device companies across all development phases from early discovery through clinical trials.
2. GLP Regulatory Studies: GLP-compliant studies for regulatory submissions including genotoxicity, toxicology, and safety pharmacology studies following OECD guidelines
3. GMP Manufacturing: GMP manufacture and clinical packaging services for Phase 1 and 2 clinical trials, including formulation development and analytical services

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Core offering

Scantox is a Nordic preclinical GLP-accredited contract research organization (CRO) providing integrated drug development services across four divisions: Discovery Services (CNS/neurology efficacy models, PK/PD, in vitro and in vivo studies via Scantox Neuro), Genetic Toxicology Services (DuplexSeq™ NGS assays, Big Blue® transgenic rodent assays, traditional genotoxicity tests), Regulatory Toxicology Services (GLP-compliant toxicology, safety pharmacology, histopathology with Göttingen Minipig expertise), and Pharmaceutical Development & Analytical Services (formulation development, GMP manufacturing, bioanalysis, clinical packaging for Phase 1/2 trials).

Product overview

Scantox is a Nordic preclinical GLP-accredited Contract Research Organization (CRO) providing integrated drug development services across four main divisions: Discovery Services (including Scantox Neuro for CNS/neurology research), Genetic Toxicology Services (featuring DuplexSeq™ Mutagenesis Assays, Big Blue®, and traditional genotoxicity assays), Regulatory Toxicology Services, and Pharmaceutical Development & Analytical Services. The company operates across multiple sites in Denmark, Sweden, Austria, and the UK following a series of strategic acquisitions including QPS Neuropharmacology, Gentronix, Solural Pharma, and Q&Q Labs AB. The integrated portfolio spans from early lead identification through regulatory safety studies to clinical trial support, enabling a 'one-stop shop' approach for pharmaceutical and biotech clients worldwide.

Differentiator

Problem solved

Functional benefit

Brands

• DuplexSeq™ Mutagenesis Assays: Error-corrected sequencing-based mutagenesis testing assays acquired from TwinStrand Biosciences for nonclinical genomic safety assessment.
• Big Blue® Transgenic Rodent Gene Mutation Assay
• Enhanced Ames Test

Products and services

• Discovery Services Comprehensive preclinical discovery services spanning in vitro and in vivo efficacy models, specializing in neurology-related pharmaceutical research and CNS drug discovery through Scantox Neuro. Includes disease models for Alzheimer's, Parkinson's, ALS, Huntington's, lysosomal storage diseases, PK/PD studies, exploratory toxicology, and local tolerance studies for pharmaceutical and biotech clients.
• Genetic Toxicology Services Comprehensive portfolio of screening and regulatory genotoxicity products and services including mutagen testing, clastogens/aneugens assessment, and GLP-compliant studies. Includes DuplexSeq™ NGS assays, Big Blue® transgenic rodent assays, Ames tests, micronucleus assays, and mouse lymphoma assays for pharmaceutical and biotech clients.
• Regulatory Toxicology Services Full spectrum of preclinical toxicology studies including GLP compliance, general toxicology, safety pharmacology, clinical pathology, and histopathology, with leading expertise using Göttingen Minipig models for pharmaceutical and biotech regulatory submissions.
• Pharmaceutical Development & Analytical Services Formulation development, dose formulation manufacturing including GMP and clinical packaging for Phase 1 and 2 trials, bioanalysis using LC-MS, ELISA, qPCR, and Immunohistochemistry, and ICH stability testing for pharmaceutical clients.
• DuplexSeq™ Mutagenesis Assays Error-corrected next-generation sequencing-based mutagenesis testing assays providing high-precision genomic safety assessment for nonclinical drug development. Acquired from TwinStrand Biosciences, Scantox is the sole global CRO provider of this proprietary technology, enabling high-sensitivity detection of low-frequency mutations for pharmaceutical and biotech clients.

Quantifiable outcome

• Integrated genomic safety platform spanning early screening through late-stage regulatory development
• +1 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core and supporting.

• LatchBiocoreTechnology or Integration · 12 May 2026LatchBio was selected to provide the cloud-based bioinformatics platform for DuplexSeq™ Mutagenesis App migration. The platform was chosen for 21 CFR Part 11 compliance, immutable audit trails, and SOC 2 Type II certified infrastructure suitable for regulated nonclinical environments. The migration restores and enhances customer access to error-corrected sequencing assays.
• Fulcrum GenomicssupportingTechnology or Integration · 12 May 2026Fulcrum Genomics supported the technical migration of the DuplexSeq™ bioinformatics pipeline to the cloud-based LatchBio platform. Clint Valentine, the original pipeline architect, led the migration confirming equivalent outputs to TwinStrand's original dataset.
• LundbeckcoreStrategic or Co-development Partner · 14 June 2024Scantox partnered with Lundbeck to develop a unique stress-free blood sampling method for Göttingen minipigs enabling deeper understanding of drug effects on circadian cortisol profiles. This innovation allows frequent blood sampling without causing pain or disturbance to animals, validated through 24-hour cortisol monitoring studies. The partnership resulted in a peer-reviewed publication demonstrating the model's relevance for neurological and stress disorder drug development.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Inotiv: US-based preclinical CRO with strong toxicology, pathology, and discovery services portfolio. Closely aligned with Scantox in service mix (in vivo toxicology, safety assessment, research models), serving similar pharma/biotech clients with project-based pricing.
• QPS Holdings: Global CRO with major focus on CNS/neuropharmacology, DMPK, and bioanalysis. Directly comparable to Scantox Neuro — Scantox acquired the neuropharmacology division of QPS Austria, leaving the parent as a competing CNS specialty CRO with overlapping capabilities and clients.

Emerging players

• Pharmaron: China-headquartered CRO with rapidly expanding preclinical, DMPK, toxicology, and bioanalytical services. Comparable to Scantox in integrated preclinical offering, with aggressive European/US expansion strategy competing for the same pharma outsourcing wallet.
• Frontage Laboratories: US/China-based CRO offering bioanalytical, preclinical, and CMC services. Overlaps with Scantox's bioanalytical and formulation development capabilities (added via Q&Q Labs and Solural Pharma acquisitions) and competes for similar biotech and specialty pharma clients.
• Toxikon (formerly Bionique Labs / Marshall BioResources-adjacent): US-based preclinical contract research organization focused on toxicology and medical device safety testing. Comparable to Scantox's regulatory toxicology and local tolerance/biocompatibility service lines, serving overlapping medical device and pharma clients.

Broad incumbents

• Charles River Laboratories: Global preclinical CRO with deep toxicology, safety assessment, and discovery capabilities. Highly comparable to Scantox's GLP toxicology and discovery services but at vastly larger scale and broader geographic footprint; sets the pricing/quality benchmark Scantox must compete against.
• WuXi AppTec: China-headquartered CRO with comprehensive preclinical toxicology, DMPK, and bioanalytical services. Competes for the same global pharma outsourcing budget as Scantox, particularly in genetic toxicology and discovery toxicology, and serves as a major non-European comparator.
• Labcorp Drug Development (formerly Covance): One of the largest CROs globally with extensive preclinical toxicology, genetic toxicology, and central laboratory services. Overlaps directly with Scantox's regulatory toxicology and genetic toxicology offerings, plus broader Phase 1 clinical packaging services.
• Eurofins Scientific: Global testing services giant with significant pharmaceutical and genetic toxicology testing operations. Comparable to Scantox on the testing/analytical side, with overlapping GLP genotoxicity and bioanalytical services, though broader scope and global reach.

Regional players

• ITR Laboratories Canada: Canadian preclinical CRO specializing in toxicology, safety pharmacology, and bioanalysis. Comparable to Scantox's regulatory toxicology division in service mix, serving pharma/biotech clients primarily in North America — a regional alternative rather than direct head-to-head European competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks4 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/scantox

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A5 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Scantox